Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

Finasteride can cause side effects like erectile dysfunction and decreased libido, possibly due to increased estradiol from testosterone aromatization, especially in those with higher body fat. Side effects vary widely and may also be influenced by genetic factors or neurosteroid inhibition.

The user has been using finasteride and minoxidil for over three years, switched to oral minoxidil, and recently started dutasteride and dermarolling but still experiences thin hair. They are seeking suggestions for improving their hair condition.

The user has been using finasteride and dutasteride for hair loss but is experiencing low energy and motivation, possibly due to high prolactin levels. Despite treatment, hairline recession continues, and the user is considering the impact of low DHT levels on overall health and energy.

The conversation is about a user's progress using oral finasteride and minoxidil for hair loss over two months. The user reports noticing small hair regrowth after the first month and discusses the convenience and cost of chewable tablets from Hims, while also addressing side effects like ED and heart palpitations.

Clascoterone, a topical anti-androgen, is generating interest for potentially fewer systemic side effects. Users are curious about its effectiveness and details like concentration and duration of use.

A user experienced severe scalp itching with MPB and found Nizoral ineffective. A doctor diagnosed seborrheic eczema and prescribed Betacap, which relieved the itching.

The conversation humorously discusses the fictional "Post PP405 Syndrome" and the idea of starting a foundation or cult around it. It mentions skepticism about the effectiveness of PP405 and jokes about future therapies.

A 28-year-old male reports progress in hair regrowth using 5mg Minoxidil and 0.5mg Dutasteride, noting improvement in the crown area. Another user shares similar positive results since starting treatment in January.

A 36-year-old man is using topical 5% Minoxidil for hair thinning and is considering adding 3mg Minoxidil pills as recommended by a dermatologist. He is concerned about potential side effects and increased shedding but cannot access Finasteride due to strict regulations.

Hair loss affects confidence, with discussions on treatments like finasteride, minoxidil, and RU58841. Emphasis is placed on self-acceptance and building confidence beyond appearance.

The conversation humorously discusses hair loss treatments, mentioning "oral miraclegro," "topical roundup," "spectracide," "Cow Dung mesotherapy," and "weekly Foot stepping sessions." The user jokingly considers switching to "weed and feed" as a treatment.

Excess sebum rich in cholesterol and triglycerides can lead to hair loss through inflammation, with treatments like Ciclopirox shampoo, Benzoyl Peroxide shampoo, and Clindamycin gel recommended for managing conditions like seborrheic dermatitis and folliculitis. Pioglitazone is suggested for Lichen Planopilaris, while Omega-3s and reducing processed foods may improve sebum quality, though genetic factors play a significant role.

MCL-1 protein may help maintain hair follicles in the growth phase and prevent miniaturization. There is interest in experimental treatments like exosomes, peptides, or stem cell serums to upregulate MCL-1 for hair loss, especially for those not using minoxidil or finasteride.

The user is happy with their 2-month progress using a 3-in-1 oral tablet containing finasteride, minoxidil, and biotin, with minor side effects like slightly lower libido. They report no significant issues like breakouts and note that oral treatments are more effective than topical ones.

The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.

The conversation discusses whether to use finasteride for hair loss, considering its role in inhibiting DHT and 5AR, which can affect brain function and mood. Some users report anxiety and depression from finasteride, while others do not experience these side effects and emphasize the importance of DHT for brain and prostate health.

The conversation is about dealing with hair loss and exploring treatments like HRT, Minoxidil, and micro-needling. The user is considering wigs and possibly a hair transplant while expressing feelings of self-doubt and seeking support.

The conversation discusses hair regrowth progress using 1mg oral finasteride and 5mg oral minoxidil daily over three years. Concerns about potential heart risks from minoxidil dosage are raised, with suggestions to consult a doctor and consider reducing the dose.

OP used finasteride 1mg and 2.5mg oral minoxidil since late April, showing hair improvement despite some initial libido issues. Users discussed side effects, costs, and alternative treatments, with OP noting increased facial hair but no significant body hair growth.

Finasteride, Minoxidil, Bioneer CosmeRNA, Technoderma, Kintor, Hope, Breezula, and Follicum treatments showed increases in hair count, with Technoderma showing the highest increase at 24.3 hairs/cm². Amplifica has not yet published results.

Sugary beverages increase the risk of pattern hair loss in men by 57%. Treatments discussed include Minoxidil, finasteride, and RU58841.

The user experienced hair regrowth after starting finasteride in September 2025 and topical minoxidil in December 2025, despite setbacks from using tretinoin gel. Their current treatment includes dutasteride, finasteride, topical minoxidil, and dermastamping.

The user is experiencing an allergic reaction to propylene glycol in Kirkland minoxidil and is considering switching to a foam version or a low-PG minoxidil solution. They are also contemplating oral minoxidil but are concerned about its long-term safety.

The conversation discusses whether using 0.1% topical finasteride alongside 0.5 mg oral finasteride is excessive, with suggestions to choose either oral or topical treatment. The user also uses 5% minoxidil and mentions concerns about alcohol-based solutions due to seborrheic dermatitis.

Despite using finasteride, minoxidil, and RU58841, the user is experiencing slow hair loss, particularly at the hairline, and is considering additional treatments like microneedling and possibly switching to dutasteride. Concerns about medication side effects, such as reduced sperm count and performance anxiety, are also discussed.

The user experienced fatigue, brain fog, and dizziness after taking Dutasteride for hair loss, suspecting it might be a side effect. They plan to consult a doctor and get blood work done, while others in the conversation discuss potential cognitive effects and compare Dutasteride to Finasteride.

Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.

High body fat can increase estrogen levels, leading to side effects when using finasteride. Reducing body fat and checking hormone levels can help manage these side effects.

A user with seborrheic dermatitis uses Ketoconazole 2% and Betamethasone and is considering starting Minoxidil for thinning hair. They are concerned about using Minoxidil and Betamethasone simultaneously.